Skip to main content
. Author manuscript; available in PMC: 2020 Aug 28.
Published in final edited form as: Adv Med Sci. 2019 Dec 13;65(1):18–29. doi: 10.1016/j.advms.2019.10.002

Fig. 4. Clinical utility of a multianalyte assay (NETest) for neuroendocrine tumor diagnosis and management.

Fig. 4.

Diagnosis: The NETest can detect lung, thymic, pancreatic, and gastrointestinal tract NETs as well as paragangliomas and pheochromocytomas (PPGL) with ≥ 90% accuracy.

Management: NETest has clinical utility in three areas: 1) Defining the status of the disease – as either stable or progressive. 2) Monitoring therapy or evaluating patients in watch-and-wait programs. 3) Determining the effectiveness of a treatment modality e.g. determining residual disease or disease “recurrence” after surgery or evaluating responses to somatostatin analogues (SSA) or peptide receptor radionuclide therapy (PRRT).